Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective
for the treatment of adolescents (ages 13-17) with schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.